TCBPY (TC BioPharm (Holdings)) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


What is TC BioPharm (Holdings) Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

TC BioPharm (Holdings)'s Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TCBPY vs SIGY, CNBX, SYGGF: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, TC BioPharm (Holdings)'s Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TC BioPharm (Holdings) Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TC BioPharm (Holdings)'s Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where TC BioPharm (Holdings)'s Margin of Safety % (DCF Earnings Based) falls into.


TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.